Company: SION
Filing Date: 2025-01-17
Form Type: S-1
Source: 0001193125-25-008474
Chunk: 255

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-01-17
Form: S-1
Chunk 255
---
 e.g., the Severance and CIC Agreements described above, that, as of the New Severance and CIC Plan Effective Date, provides for more favorable terms or provisions than provided under such New
Severance and CIC Plan, then the more favorable definition, term or provision, or relevant combination thereof, will be applicable for the benefit of the eligible employee; provided, however, that there is no duplication of benefits and (i) a
more favorable definition of “cause” under an employee non-competition agreement shall not apply for purposes of “cause” as used in New Severance and CIC Plan and (ii) the following
provisions under any Existing Employment Agreement will continue to apply to any equity awards granted before the New Severance and CIC Plan Effective Date, but will not apply to any equity awards granted after the New Severance and CIC Plan
Effective Date: (A) extending the time for exercising any stock-based awards beyond 3 months following a termination of service (other than due to death or disability), (B) providing for acceleration of vesting of unvested equity award(s) upon
a termination of employment prior to a change in control or other sales transaction of the Company; and/or (C) providing for acceleration of vesting of unvested equity award(s) upon a change in control or other sales transaction of the Company.

185

Compensation Recovery Policy In accordance with the requirements of the Dodd-Frank Act, final SEC rules, and applicable Nasdaq listing standards, on December 12, 2024, our board of directors adopted a compensation recovery policy in connection with this offering, which will become effective upon the date on which the registration statement of which this prospectus forms a part is declared effective by the SEC. The compensation recovery policy will provide that in the event we are required to prepare a restatement of financial statements due to material noncompliance with any financial reporting requirement under securities laws, we will seek to recover any incentive-based compensation that was based upon the attainment of a financial reporting measure and that was received by any current or former executive officer during the three-year period preceding the date that the restatement was required if such compensation exceeds the amount that the executive officer would have received had the financial results been properly reported. Outstanding Equity Awards at Fiscal 2024 Year-End The following table sets forth information concerning outstanding equity awards held by our NEOs as of December 31, 2024.

|                         |     |            |           |     |